Q: Is there a vaccine for West Nile virus?

No approved human vaccine exists, despite extensive development efforts. Multiple vaccine candidates have been tested — including inactivated WNV vaccines, chimeric flavivirus vaccines (ChimeriVax-WN) and DNA vaccines. Development has been hampered by: seasonal and unpredictable disease; ethical challenges of conducting efficacy trials; and commercial uncertainties. Several veterinary vaccines for horses are approved in the US. Human vaccine development is ongoing.

Q: Why is WNV now endemic in Europe?

WNV was first detected in Europe (Romania) in 1996. It re-emerged in 2004 (Russia, Romania), expanded southward and by 2018 caused the largest European epidemic ever recorded (1,559 neuroinvasive cases). Factors driving European spread: migratory birds (carrying WNV from Africa/Middle East); competent local Culex mosquito populations; warm, dry summers favouring Culex breeding; and — with climate change — expanding Culex range and longer transmission seasons. WNV is now considered permanently established in southern Europe.

Q: Who is at highest risk of severe disease?

Risk factors for neuroinvasive WNV disease: age over 60 (most important — approximately 20-fold higher risk than young adults); immunocompromised status (organ transplant recipients, HIV, haematological malignancies — greatest vulnerability); diabetes; hypertension; and kidney disease. The risk for a healthy young adult is approximately 1 in 150 infections; for an elderly immunocompromised individual it may exceed 1 in 10.

Q: How is severe WNV treated?

No specific antiviral is approved. Management of neuroinvasive WNV is supportive: ICU monitoring and care; mechanical ventilation for respiratory failure; control of cerebral oedema; anticonvulsants for seizures; management of comorbidities. Intravenous immunoglobulin and interferon-alpha have been used in some cases without definitive evidence. Rehabilitation for survivors of encephalitis and acute flaccid paralysis may be prolonged.

Q: Does Georgia have WNV?

The South Caucasus region has documented WNV transmission — with cases reported in Azerbaijan and Armenia, and serological evidence of circulation in Georgia. The region's position on migratory bird flyways connecting Africa and Asia to Europe creates conditions for WNV transmission. PHIG maintains arboviral disease surveillance as part of Georgia's health security programme. Healthcare providers should include WNV in the differential diagnosis of unexplained encephalitis, particularly in summer and autumn.

Q: How does GMJ News cover WNV?

GMJ News covers ECDC WNV surveillance updates, European epidemic data, South Caucasus transmission, blood safety implications and the arboviral disease emergence context. WNV is relevant to PHIG's epidemiological surveillance and the Georgian Medical Journal's infectious disease coverage.

Question 1

What is West Nile virus?

Accepted Answer

West Nile virus is a mosquito-borne flavivirus — related to dengue, yellow fever and Zika — transmitted primarily by Culex mosquitoes that feed on infected birds. It is now the most geographically widespread flavivirus globally, established in Africa, Europe, the Middle East, Asia, Australia and the Americas. The vast majority of human infections are asymptomatic or cause mild febrile illness; less than 1% cause severe neuroinvasive disease — encephalitis, meningitis or acute flaccid paralysis.

Question 2

How is WNV transmitted?

Accepted Answer

Primary route: bites of infected Culex mosquitoes — which acquire WNV from viraemic birds (the reservoir hosts) and transmit it to humans and horses during subsequent blood meals. Humans cannot infect mosquitoes (dead-end hosts). Other routes: blood transfusion (NAT screening required in endemic areas during season); organ transplantation; breast milk; transplacental (rare). Person-to-person transmission does NOT occur.

Question 3

What are the symptoms?

Accepted Answer

Asymptomatic (80%): no symptoms. West Nile fever (19-20%): sudden onset fever, headache, fatigue, muscle aches, nausea, vomiting and — characteristically — a skin rash in approximately 50%. Self-limiting over 3-6 days. Neuroinvasive disease (<1%): West Nile encephalitis (altered consciousness, cognitive changes, weakness, movement disorders — tremor, parkinsonism); West Nile meningitis (fever, headache, neck stiffness, photophobia); and acute flaccid paralysis (polio-like, from anterior horn cell involvement — may be permanent).

Question 4

Is there a vaccine for West Nile virus?

Accepted Answer

No approved human vaccine exists, despite extensive development efforts. Multiple vaccine candidates have been tested — including inactivated WNV vaccines, chimeric flavivirus vaccines (ChimeriVax-WN) and DNA vaccines. Development has been hampered by: seasonal and unpredictable disease; ethical challenges of conducting efficacy trials; and commercial uncertainties. Several veterinary vaccines for horses are approved in the US. Human vaccine development is ongoing.

Question 5

Why is WNV now endemic in Europe?

Accepted Answer

WNV was first detected in Europe (Romania) in 1996. It re-emerged in 2004 (Russia, Romania), expanded southward and by 2018 caused the largest European epidemic ever recorded (1,559 neuroinvasive cases). Factors driving European spread: migratory birds (carrying WNV from Africa/Middle East); competent local Culex mosquito populations; warm, dry summers favouring Culex breeding; and — with climate change — expanding Culex range and longer transmission seasons. WNV is now considered permanently established in southern Europe.

Question 6

Who is at highest risk of severe disease?

Accepted Answer

Risk factors for neuroinvasive WNV disease: age over 60 (most important — approximately 20-fold higher risk than young adults); immunocompromised status (organ transplant recipients, HIV, haematological malignancies — greatest vulnerability); diabetes; hypertension; and kidney disease. The risk for a healthy young adult is approximately 1 in 150 infections; for an elderly immunocompromised individual it may exceed 1 in 10.

Question 7

How is severe WNV treated?

Accepted Answer

No specific antiviral is approved. Management of neuroinvasive WNV is supportive: ICU monitoring and care; mechanical ventilation for respiratory failure; control of cerebral oedema; anticonvulsants for seizures; management of comorbidities. Intravenous immunoglobulin and interferon-alpha have been used in some cases without definitive evidence. Rehabilitation for survivors of encephalitis and acute flaccid paralysis may be prolonged.

Question 8

Does Georgia have WNV?

Accepted Answer

The South Caucasus region has documented WNV transmission — with cases reported in Azerbaijan and Armenia, and serological evidence of circulation in Georgia. The region's position on migratory bird flyways connecting Africa and Asia to Europe creates conditions for WNV transmission. PHIG maintains arboviral disease surveillance as part of Georgia's health security programme. Healthcare providers should include WNV in the differential diagnosis of unexplained encephalitis, particularly in summer and autumn.

Question 9

How does GMJ News cover WNV?

Accepted Answer

GMJ News covers ECDC WNV surveillance updates, European epidemic data, South Caucasus transmission, blood safety implications and the arboviral disease emergence context. WNV is relevant to PHIG's epidemiological surveillance and the Georgian Medical Journal's infectious disease coverage.

GMJ News

West Nile Virus

Key messages

Key statistics

Glossary of key terms

Latest GMJ coverage

Frequently asked questions 12 Q&A — structured for Google featured snippets and AI discovery

Knowledge hub: guidelines, conventions and reports

Organizations working in migration and health

Related health topics

Company